# BLA / NDA / MAA (marketing applications) and PDUFA dates

Source: https://onco.cc/terms/bla-nda/  
OnCo record `bla-nda` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The formal application to sell a drug: a New Drug Application for small molecules, a Biologics License Application for antibodies and cell therapies (US), or a Marketing Authorisation Application (EU). The PDUFA date is the deadline by which the FDA has promised a decision.

## Summary

Applications run to hundreds of thousands of pages covering trials, manufacturing and labelling. Under the Prescription Drug User Fee Act the FDA commits to act within 10 months of filing acceptance (standard) or 6 months (priority review), plus a 60-day filing period, so 'PDUFA date' is watched by patients and investors alike. Real-Time Oncology Review and rolling submissions shorten the clock; Project Orbis coordinates review with other countries. Outcomes are approval, a complete response letter, or (rarely) withdrawal by the sponsor. Supplemental applications (sBLA/sNDA) add indications to existing drugs.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: BLA; NDA; MAA; biologics license application; new drug application; marketing authorisation application; marketing application; regulatory submission; filing accepted; submission accepted; regulatory review; PDUFA; PDUFA date; action date; target action date; goal date; rolling submission; standard review; 10-month review; 6-month review; new drug applications; regulatory submissions

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act
- Wikipedia: https://en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act

## Connected records

- terms: [Breakthrough Therapy / Priority Review / Priority Voucher](https://onco.cc/terms/breakthrough-designation/), [Complete response letter (CRL)](https://onco.cc/terms/complete-response-letter/), [Fast Track and RMAT designations](https://onco.cc/terms/fast-track-rmat/), [FDASIA 2012 and the origins of the expedited programmes](https://onco.cc/terms/fdasia-2012/), [Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments](https://onco.cc/terms/fdca/), [Full (traditional, regular) approval](https://onco.cc/terms/full-approval/), [Label, indication and label expansion](https://onco.cc/terms/label-indication/), [ODAC (Oncologic Drugs Advisory Committee)](https://onco.cc/terms/odac/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/), [Project Orbis](https://onco.cc/terms/project-orbis/), [Real-Time Oncology Review (RTOR) and Assessment Aid](https://onco.cc/terms/real-time-oncology-review/), [Regulation (EC) No 726/2004: the EU centralised procedure](https://onco.cc/terms/eu-regulation-726-2004/), [Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)](https://onco.cc/terms/regulatory-agencies/), [Trial lifecycle: from protocol to label](https://onco.cc/terms/trial-lifecycle/)
- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- people: [Chris Decker](https://onco.cc/people/chris-decker/), [Huang Guo](https://onco.cc/people/huang-guo/)

---
JSON: https://onco.cc/api/v1/entities/bla-nda.json